Video

Patricia Coyle from Stony Brook Medicine: Teri-PRO Trial shows Continued Benefits of Aubagio

Author(s):

When a medication is approved the data from that time can sometimes be of more value than the trials leading up to the approval. For Aubagio there was a recent study done looking at patient satisfaction and other issues following the approval.

When a medication is approved the data from that time can sometimes be of more value than the trials leading up to the approval. For Aubagio there was a recent study done looking at patient satisfaction and other issues following the approval.

Patricia K. Coyle, MD, from Stony Brook Medicine discussed the results of the Teri-PRO trial during the annual ECTRIMS conference in London. Coyle noted that the results focused more on patient reported results and issues than earlier trials. Through one year of research Coyle said there were definite benefits shown which was encouraging not only to the patients but also their providers as well.

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.